MedTrace Logo

GilteRInf 2022 Study (Gilteritinib Related Infections)

NCT05791890 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2023-03-30

No results posted yet for this study

Summary

The study is observational, retrospective-prospective, multicenter "real-life" study involving 26 centers belonging to the SEIFEM group. The goal of this study is to obtain a real-life experience in the management and outcome of infectious issues of patients with relapsed/resistant acute myeloid leukemia who receive Gilteritinib therapy, given that recent approval of this drug.

Conditions

Interventions

DRUG

Gilteritinib

observational study to evaluate the incidence of infections during therapy with Gilteritinb

Sponsors & Collaborators

  • University of Rome Tor Vergata

    lead OTHER

Principal Investigators

  • Maria Ilaria Del Principe, Prof · University of Rome Tor Vergata

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2024-05-31
Completion
2024-12-31
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05791890 on ClinicalTrials.gov